Summary:
A phase 2/3, interventional safety, pharmacokinetics, and efficacy, open-label, multi-center, single-arm study to investigate orally administered pf-07321332 (nirmatrelvir)/ritonavir in nonhospitalized symptomatic pediatric participants with covid-19 who are at risk of progression to severe disease.
Qualified Participants Must:
• Ages birth to less than or equal to 18 years old
• confirmed SARS-CoV2 infection
• has at least 1 underlying medical characteristic associated with an increased risk of developing COVID-19 including Overweight or Obese, Immunosuppressive disease, Chronic Lung Disease, known Hypertension, Cardiovascular Disease, Type 1 or Type 2 Diabetes Mellitus, Chronic Kidney Disease, Sickle Cell Disease, Neurodevelopmental disorder
Qualified Participants May Receive:
Compensation may be available for qualified study participants